Conserv:
Is an American company based in Birmingham, AL, specializing in environmental monitoring for the preservation of cultural heritage collections. Its clients, including institutions like the Smithsonian and the US Army, rely on Conserv’s sensors and software to maintain optimal conditions for art, photographs, textiles, and other priceless artifacts. Conserv’s continuous, automated data on temperature, humidity, vibration, light, and pests supports conservators in creating ideal physical environments for their collections.
Contrail Capital invested in the company in 2024 and will assist the company with its European expansion.
Scantrust:
Is a Swiss company headquartered at the EPFL Innovation Park in Lausanne, Switzerland. It is a leading anti-counterfeiting and connected packaging technology provider. Its mission revolves around helping companies establish connections with customers, combat counterfeiting, and enhance supply chain transparency.
Contrail Capital invested in the company in 2024 and will support the company’s expansion in the United States.
Matis:
Is a French company specializing in the creation of bespoke, high-end art installations. Based in Paris, Matis collaborates with artists, designers, and institutions worldwide to bring visionary concepts to life. Its offerings range from intricate sculptures to expansive digital displays, all crafted with meticulous attention to detail. Matis is dedicated to fostering innovation in the intersection of art and technology, providing tailored solutions that enhance cultural spaces and inspire audiences globally.
Contrail Capital invested in the company in 2024 and will support the company’s expansion in the United States and Europe.
Aceandcompany:
Is a global private equity firm headquartered in Geneva, Switzerland, with additional offices in London, New York, and Cairo. ACE & Company focuses on providing unique investment opportunities across multiple asset classes, including private equity, venture capital, and real estate. The firm partners with entrepreneurs and investors to drive growth and innovation, leveraging its deep industry expertise and extensive network. ACE & Company is committed to creating value for its stakeholders while maintaining a strong emphasis on sustainability and responsible investing.
Contrail Capital invested in the company in 2024 and will assist the company with its European expansion.
Nezasa:
Is a Swiss-based technology company focused on delivering advanced travel planning solutions. With headquarters in Zurich, Nezasa provides a platform that empowers travel agencies, tour operators, and travel brands to create, book, and manage personalized itineraries with ease. Its technology leverages real-time data and dynamic content to deliver seamless and customizable travel experiences. Nezasa is committed to enhancing the travel industry through its cutting-edge software, enabling travel providers to offer better, more efficient services to their clients worldwide.
Contrail Capital invested in the company in 2024 and will support the company’s expansion in the United States and Europe.
Positrigo:
Based in Zurich, Positrigo AG is a cutting-edge medtech company specializing in ultra-compact brain PET imaging systems. A spin-off from ETH Zurich, Positrigo develops NeuroLF — an award-winning brain PET scanner that delivers high-quality functional images in a compact design suitable for clinical environments without major infrastructure changes.
With CE marking in Europe and FDA clearance in the US, NeuroLF is a breakthrough in neurological diagnostics, addressing conditions such as Alzheimer’s, epilepsy, and brain tumors. Recognized with the iF DESIGN AWARD 2025, Positrigo combines innovation and precision engineering to make advanced brain imaging accessible and practical for clinical use worldwide.
Contrail Capital invested in the company in April 2025 and will support the company’s expansion in the United States and Europe.
With CE marking in Europe and FDA clearance in the US, NeuroLF is a breakthrough in neurological diagnostics, addressing conditions such as Alzheimer’s, epilepsy, and brain tumors. Recognized with the iF DESIGN AWARD 2025, Positrigo combines innovation and precision engineering to make advanced brain imaging accessible and practical for clinical use worldwide.
Contrail Capital invested in the company in April 2025 and will support the company’s expansion in the United States and Europe.
